Chemo-drugs used to treat cancer or other malignancies can damage peripheral nerves of the patient causing substantial nerve pain: a condition called Chemotherapy-Induced Peripheral Neuropathy (CIPN). Once initiated, for some patients this condition can last for weeks, months or even years after treatment and, further, can predisposethe patient to to other nerve damage by other causes, such as diabetes. It is not usual for this often debilitating condition to cause patients to choose not to complete their full course of chemotherapy: adversely affecting outcome. With ties to Duke University, through effective employment - and use of topical therapeutics - TRPblue is addressing the development and availability of CIPN relief for cancer patients.developing a unique, dual acting inhibitor that targets transient receptor potential (TRP) cation channels TRPV4 and TRPA1. TRPblue's small molecule antagonists preferentially attenuate signaling of these calcium-permeable channels with proven efficacy in several acute pain and chemical denervation nerve-pain models. These inhibitors have also demonstrated anti-pruritic, anti-fibrotic and anti-inflammatory activity in relevant preclinical models.
